Context Therapeutics Inc.
CNTX
$2.36
-$0.12-4.84%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.60% | 0.65% | 13.13% | 11.67% | 9.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 220.26% | -43.26% | 215.96% | 44.61% | -37.83% |
| Operating Income | -220.26% | 43.26% | -215.96% | -44.61% | 37.83% |
| Income Before Tax | -289.65% | 44.48% | -291.55% | -24.80% | 50.62% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -289.65% | 44.48% | -291.55% | -24.80% | 50.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -289.65% | 44.48% | -291.55% | -24.80% | 50.62% |
| EBIT | -220.26% | 43.26% | -215.96% | -44.61% | 37.83% |
| EBITDA | -220.39% | 43.28% | -216.08% | -44.60% | 37.85% |
| EPS Basic | -235.29% | 53.07% | -126.10% | 79.06% | 90.38% |
| Normalized Basic EPS | -235.29% | 53.10% | -126.56% | 79.04% | 90.38% |
| EPS Diluted | -235.29% | 53.07% | -126.10% | 79.06% | 90.38% |
| Normalized Diluted EPS | -235.29% | 53.10% | -126.56% | 79.04% | 90.38% |
| Average Basic Shares Outstanding | 16.18% | 18.27% | 73.20% | 496.18% | 413.15% |
| Average Diluted Shares Outstanding | 16.18% | 18.27% | 73.20% | 496.18% | 413.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |